35981-63-6

Usage

Uses

Used in Medicinal Chemistry and Drug Development:
2-(pyrrolidin-1-yl)pyridin-4-aMine is utilized as a molecular scaffold for the design and synthesis of new pharmaceutical agents, leveraging its ability to interact with biological targets. This interaction is crucial for the development of drugs that can modulate receptor activity or inhibit enzymatic processes, thereby addressing various therapeutic needs.
Used in Organic Synthesis:
In the realm of organic synthesis, 2-(pyrrolidin-1-yl)pyridin-4-aMine serves as a valuable building block. Its incorporation into more complex chemical structures facilitates the creation of novel compounds with potential applications across various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Pharmaceutical Industry for Structure-Activity Relationship Studies:
The unique molecular structure of 2-(pyrrolidin-1-yl)pyridin-4-aMine makes it an indispensable tool in the pharmaceutical industry for understanding the relationship between a compound's structure and its biological activity. This knowledge is vital for optimizing drug candidates, enhancing their efficacy, and minimizing potential side effects.

Upstream product

• 35981-61-4 4-nitro-2-pyrrolidin-1-ylpyridine-1-oxide 
• 123-75-1 pyrrolidine 
• 14432-12-3 4-Amino-2-chloropyridine 
• 914397-51-6 4-nitro-2-(pyrrolidin-1-yl)pyridine 

Relevant academic research and scientific papers

Selective Functionalization of Aminoheterocycles by a Pyrylium Salt

The functionalization of aminoheterocycles by using a pyrylium tetrafluoroborate reagent (Pyry-BF4) is presented. This reagent efficiently condenses with a great variety of heterocyclic amines and primes the C?N bond for nucleophilic aromatic substitution. More than 60 examples for the formation of C?O, C?N, C?S, or C?SO2R bonds are disclosed herein. In contrast to C?N activation through diazotization and polyalkylation, this method is characterized by its mild conditions and impressive functional-group tolerance. In addition to small-molecule derivatization, Pyry-BF4 allows the introduction of functional groups in a late-stage fashion to furnish highly functionalized structures.

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel aminomethyl-phenol derivatives of formula I wherein R1 to R4, X, A and B are as defined for formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention

SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.

8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

2-AMINOQUINAZOLINE DERIVATIVES

2-Aminoquinazoline derivatives represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R1 and R2 are each independently hydrogen, substituted or unsubstituted lower alkyl, or the like; X is a bond or CR7aR7b (wherein R7a and R7b are each independently hydrogen or the like); when X is a bond, R3 is substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group, while when X is CR7aR7b, R3 is substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, or the like; R4 is hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or the like; and R5 is hydrogen, substituted or unsubstituted aryl, or the like.